Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

30 Jun 2026, 13:55 UTC · 1h ago

Theravance Stock Down 3% After Zymeworks Announces Buyout

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Theravance's lead candidate, ampreloxetine, failed to meet primary and secondary endpoints in the pivotal phase III CYPRESS study. — The failure of a lead clinical candidate is a material blow to a biotech company's long-term growth pipeline and intrinsic value.
-0.80
2
Zymeworks Inc. has entered a definitive agreement to acquire Theravance Biopharma (TBPH) in an all-cash transaction valued at approximately $929 million. — M&A activity provides a concrete valuation floor and liquidity event for shareholders of the acquired company.
+0.60
3
Theravance shareholders will receive $17.00 in cash per share, plus a contingent value right for 80% of future proceeds from specific assets. — The specific cash offer and CVR provide a clear exit price and potential upside, though the market reacted slightly negatively to the premium levels.
+0.40
4